“We are highly encouraged by these new preclinical data which indicate that therapeutic depletion of CCR8 positive tumor infiltrating Tregs results in robust anti-tumorigenic activity in both checkpoint inhibition-resistant and checkpoint inhibition-susceptible tumor models,” said
Summary of key data
- In human CCR8 knock-in mice, SRF114, a fully human antibody targeting human CCR8, conferred robust anti-tumor activity and reshaped the tumor microenvironment towards a proinflammatory milieu.
- In different in vivo models, SRF114 monotherapy or treatment with a murine surrogate antibody promoted expansion of CD8+ effector T cells and increased the production of pro-inflammatory molecules including IFNγ, TNFα, and granzyme A in a checkpoint-resistant tumor model.
- Anti-CCR8 therapy resulted in depletion of tumor Tregs without impacting peripheral lymphoid Treg cell populations and led to increases in the levels of co-stimulatory molecules CD80 and CD86 in a subset of tumor myeloid cells.
- Anti-CCR8 and anti-PD-1 combination therapy increased tumor immune cell infiltration, cytokine production and improved overall survival in a checkpoint inhibitor resistant melanoma model.
Poster Session Information
Title: Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu
Abstract number: 5125
Session category: Immunology
Session title: Combination Immunotherapies 2
Session date and time:
A copy of the poster will be available on the Posters & Publications page of the company’s website following the presentation.
SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment. In preclinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intratumoral Treg cells. In addition, SRF114 reduced tumor growth in murine models. These findings support the advancement of SRF114 as a therapeutic candidate that holds the potential to drive anti-tumor immunity in patients.
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114 which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Vice President, Investor Relations and Corporate Communications
+1 617 865 3250
Source: Surface Oncology, Inc.